Neurology and Therapy

Neurology and Therapy

神经病学和治疗
NEUROL THER
影响因子:4.8
JCR分区:Q1
新锐分区:医学2区
是否综述期刊:N/A
是否预警:不在预警名单内
是否OA:
出版国家/地区:ENGLAND
出版社:SPRINGER LONDON LTD
发刊时间:0
收录数据库:SCIE/Scopus收录/DOAJ开放期刊
ISSN:2193-8253

期刊介绍

Aims and Scope Neurology and Therapy aims to provide reliable and inclusive, rapid publication for all therapy related research for neurological indications, supporting the timely dissemination of research with a global reach, to help advance scientific discovery and support clinical practice. Neurology and Therapy is an international, open access, peer reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of neurological and psychiatric therapies, (also covering surgery and devices). Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, case reports, trial designs, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Neurology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted, it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model, this allows for the rapid and efficient communication of the latest research and reviews to support scientific discovery and clinical practice. Open Access All articles published by Neurology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital Features and Plain Language Summaries Neurology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviews conflict, an Editorial Board Member will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed. Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised, it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments, if appropriate. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Neurology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.
目的和范围神经病学与治疗旨在为所有神经病学适应症的治疗相关研究提供可靠、包容、快速的出版物,支持研究在全球范围内的及时传播,以帮助推进科学发现和支持临床实践。神经病学与治疗是一个国际性、开放获取、同行评审、快速出版的期刊,致力于出版高质量的临床(所有阶段),围绕神经和精神疗法的发现、开发和使用进行的观察性、真实世界和健康结局研究, (也涵盖手术和器械)。该杂志也欢迎与诊断、药物经济学、公共卫生、生活质量、患者护理、管理和教育相关的研究。该杂志是广大医疗保健专业人士感兴趣的杂志,发表原创研究、综述、病例报告、试验设计、通信和信件。该杂志面向全球读者,并收到来自世界各地的投稿。神经病学和治疗将考虑所有科学合理的研究,无论是积极的,证实性的或消极的数据。无论是针对国际和/或特定国家的受众,我们都欢迎提交材料,当研究人员试图针对更特定的患者人群时,这一点至关重要。这种包容性的方法使该杂志能够协助传播所有科学和道德上健全的研究。快速出版该杂志的快速出版时间表旨在在提交后2周内做出同行评审决定。如果一篇文章被接受,它将在接受后的3 - 4周内在线发表。这些快速的时间表是通过一个专门的内部编辑团队,谁密切管理文章的工作流程,和一个广泛的编辑和顾问委员会,谁协助快速同行审查相结合。这使得该杂志能够支持研究的快速传播,同时仍然提供强大的同行评议。结合期刊的开放存取模式,这使得最新的研究和评论能够快速有效地交流,以支持科学发现和临床实践。
年发文量 115
国人发稿量 0
国人发文占比 0%
自引率 4.2%
平均录取率-
平均审稿周期 6 Weeks
版面费 EUR5500; USD6850; GBP4700
偏重研究方向 CLINICAL NEUROLOGY-

期刊高被引文献

Deep Learning and Neurology: A Systematic Review
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00153-8
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00160-9
A Review on MS-Based Blood Biomarkers for Alzheimer’s Disease
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00165-4
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00168-1
Diagnosing and Treating Depression in Patients with Alzheimer’s Disease
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00148-5
An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0129-0
Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00152-9
Reflections on the Utility of the Retina as a Biomarker for Alzheimer’s Disease: A Literature Review
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00173-4
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0127-2
Fingolimod Immune Effects Beyond Its Sequestration Ability
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00162-7
Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00156-5
Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00169-0
Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00166-3
Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00154-7
Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0131-6
Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0138-z
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00164-5
Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00167-2
Therapy of Sialorrhea with Botulinum Neurotoxin
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00155-6
Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0141-4
Late Onset of Neuromyelitis Optica Spectrum Disorders
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0143-2
Cognitive Fatigability Interventions in Neurological Conditions: A Systematic Review
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00158-3
Effect of Anodal tDCS on Articulatory Accuracy, Word Production, and Syllable Repetition in Subjects with Aphasia: A Crossover, Double-Blinded, Sham-Controlled Trial
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00149-4
Targeting Higher Levels of Tau Protein in Ukrainian Patients with Wilson’s Disease
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0134-3
Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0144-1
A Novel Dual-Frequency Deep Brain Stimulation Paradigm for Parkinson’s Disease
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0140-5
Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00172-5
The Treatment of Hypersalivation in Rett Syndrome with Botulinum Toxin: Efficacy and Clinical Implications
来源期刊:Neurology and TherapyDOI:10.1007/s40120-018-0125-9
Cerebrolysin as a New Treatment Option for Post-Stroke Spasticity: Patient and Physician Perspectives
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0128-1
Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00175-2
Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0145-0
PatientConcept App: Key Characteristics, Implementation, and its Potential Benefit
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0133-4
Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0139-y
Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged\u2009≥\u200960 Versus\u2009<\u200960 Years: A Subanalysis from the Euro-Esli Study
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0137-0
Exercise in Multiple Sclerosis: Knowing is Not Enough—The Crucial Role of Intention Formation and Intention Realization
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0136-1
Intravenous Milrinone Salvage Therapy in Acute Internal Carotid Artery Occlusion: Case Report
来源期刊:Neurology and TherapyDOI:10.1007/s40120-018-0124-x
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00159-2
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00171-6
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0146-z
Neurology and Therapy: Looking Back on 2018 and Forward to 2019
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0126-3
Abstracts from the 5th International Porto Congress of Multiple Sclerosis
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0135-2
A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00174-3
Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00170-7
Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00150-x
Adapting the Goal Attainment Approach for Major Depressive Disorder
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00151-w
Correction to: Abstracts from the 5th International Porto Congress of Multiple Sclerosis
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00161-8
Risperdal® CONSTA® Needle Detachment. Incidence Rates Before and After Kit Redesign: A Retrospective Study using Electronic Health Records and Natural Language Processing in the Department of Veterans Affairs
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0130-7
Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0132-5
Acknowledgement to Authors, Referees and Readers 2019
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-00163-6
Case Report of a Novel Technique for Repair of the Vertebral Artery During Cranial Surgery
来源期刊:Neurology and TherapyDOI:10.1007/s40120-019-0142-3

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
80.87%99.7%-1.89%

相关指数

影响因子
影响因子
年发文量
自引率

预警情况

查看说明
时间 预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》

JCR分区

WOS分区等级:1区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
CLINICAL NEUROLOGY
Q1

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2026年3月发布
(新锐分区)
医学2区
CLINICAL NEUROLOGY 临床神经病学
3区
N/A
2025年3月升级版
医学3区
CLINICAL NEUROLOGY 临床神经病学
3区
2023年12月旧的升级版
医学3区
CLINICAL NEUROLOGY 临床神经病学
3区

CiteScore

查看说明
CiteScore SJR SNIP 学科 分区 排名
7.20
1.376
1.262
大类:Medicine 小类:Neurology (clinical)
大类:Medicine 小类:Neurology
Q1
Q1
74 / 400
38 / 194

相关文章